Page last updated: 2024-08-21

quinazolines and osi 027

quinazolines has been researched along with osi 027 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L	1
Becker, MN; Copland, JA; Kreinest, PA; Marlow, LA; Vonroemeling, CA; Williams, CR; Wu, KJ	1

Other Studies

2 other study(ies) available for quinazolines and osi 027

Article	Year
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays	2012
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urologic oncology, 2014, Volume: 32, Issue:3 Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms	2014

Article

Year

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:11

Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays

2012

The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.

Urologic oncology, 2014, Volume: 32, Issue:3

Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Indoles; Lapatinib; Male; Purines; Quinazolines; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazines; Urinary Bladder Neoplasms

2014